Lissa, Delphine
Takahashi, Nobuyuki
Desai, Parth
Manukyan, Irena http://orcid.org/0000-0003-2437-0500
Schultz, Christopher W.
Rajapakse, Vinodh
Velez, Moises J.
Mulford, Deborah
Roper, Nitin
Nichols, Samantha
Vilimas, Rasa
Sciuto, Linda
Chen, Yuanbin
Guha, Udayan http://orcid.org/0000-0003-1087-9218
Rajan, Arun http://orcid.org/0000-0003-2776-3385
Atkinson, Devon http://orcid.org/0000-0002-6675-1531
El Meskini, Rajaa http://orcid.org/0000-0003-3238-7038
Weaver Ohler, Zoe http://orcid.org/0000-0002-6287-2504
Thomas, Anish http://orcid.org/0000-0003-3293-3115
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC 011793)
Article History
Received: 9 February 2021
Accepted: 16 March 2022
First Online: 19 April 2022
Competing interests
: D.L. in an employee of AstraZeneca. A.T. report research funding to the institution from the following entities: EMD Serono, AstraZeneca, Tarveda Therapeutics, Prolynx Inc, and Immunomedics. The other authors have no competing interest to declare. None of the authors have competing non-financial interests.